MXPA05009687A - Uso de derivados de isoquinolina para tratar cancer y enfermedades relacionadas con cinasa map. - Google Patents

Uso de derivados de isoquinolina para tratar cancer y enfermedades relacionadas con cinasa map.

Info

Publication number
MXPA05009687A
MXPA05009687A MXPA05009687A MXPA05009687A MXPA05009687A MX PA05009687 A MXPA05009687 A MX PA05009687A MX PA05009687 A MXPA05009687 A MX PA05009687A MX PA05009687 A MXPA05009687 A MX PA05009687A MX PA05009687 A MXPA05009687 A MX PA05009687A
Authority
MX
Mexico
Prior art keywords
map kinase
treating cancer
related diseases
isoquinoline derivatives
kinase related
Prior art date
Application number
MXPA05009687A
Other languages
English (en)
Spanish (es)
Inventor
Lloyd Sabio Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05009687A publication Critical patent/MXPA05009687A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
MXPA05009687A 2003-03-11 2004-03-10 Uso de derivados de isoquinolina para tratar cancer y enfermedades relacionadas con cinasa map. MXPA05009687A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
PCT/EP2004/002460 WO2004080464A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Publications (1)

Publication Number Publication Date
MXPA05009687A true MXPA05009687A (es) 2005-10-20

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009687A MXPA05009687A (es) 2003-03-11 2004-03-10 Uso de derivados de isoquinolina para tratar cancer y enfermedades relacionadas con cinasa map.

Country Status (22)

Country Link
EP (1) EP1603566B1 (enExample)
JP (1) JP2006519807A (enExample)
KR (1) KR20050108383A (enExample)
CN (1) CN1758910A (enExample)
AT (1) ATE421324T1 (enExample)
AU (1) AU2004218914A1 (enExample)
BR (1) BRPI0408257A (enExample)
CA (1) CA2518530A1 (enExample)
DE (1) DE602004019193D1 (enExample)
ES (1) ES2318276T3 (enExample)
HR (1) HRP20050788A2 (enExample)
IS (1) IS8064A (enExample)
MA (1) MA27724A1 (enExample)
MX (1) MXPA05009687A (enExample)
NO (1) NO20054647L (enExample)
PL (1) PL1603566T3 (enExample)
PT (1) PT1603566E (enExample)
RU (1) RU2325159C2 (enExample)
TN (1) TNSN05223A1 (enExample)
TW (1) TW200501955A (enExample)
WO (1) WO2004080464A1 (enExample)
ZA (1) ZA200506571B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors
HRP20110839T1 (hr) * 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag B−Rafキナーゼ阻害剤に対する感受性についての診断試験
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
AU2004218914A1 (en) 2004-09-23
TNSN05223A1 (en) 2007-06-11
RU2005131168A (ru) 2006-05-27
HRP20050788A2 (en) 2006-12-31
JP2006519807A (ja) 2006-08-31
ES2318276T3 (es) 2009-05-01
TW200501955A (en) 2005-01-16
EP1603566A1 (en) 2005-12-14
BRPI0408257A (pt) 2006-03-07
WO2004080464A1 (en) 2004-09-23
IS8064A (is) 2005-10-10
CA2518530A1 (en) 2004-09-23
EP1603566B1 (en) 2009-01-21
NO20054647D0 (no) 2005-10-10
ZA200506571B (en) 2006-07-26
RU2325159C2 (ru) 2008-05-27
DE602004019193D1 (de) 2009-03-12
CN1758910A (zh) 2006-04-12
ATE421324T1 (de) 2009-02-15
NO20054647L (no) 2005-12-09
MA27724A1 (fr) 2006-01-02
PL1603566T3 (pl) 2009-07-31
PT1603566E (pt) 2009-04-27
KR20050108383A (ko) 2005-11-16

Similar Documents

Publication Publication Date Title
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
TNSN05223A1 (en) Use of isoquinoline derivatives for treating cancer and map kinase related diseases
ES2176251T3 (es) Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
GB0112348D0 (en) Compounds
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
BRPI0411365A (pt) derivados de aminopiridina
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
MX2009009574A (es) Tratamiento de melanoma.
TNSN07294A1 (en) Treatment of metastasized tumors
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
NO20050640L (no) Rutenium anticancer komplekser
TW200504051A (en) Novel acridine derivatives and their use as medicaments
ATE386029T1 (de) Urokinase-inhibitoren
DE502004007950D1 (en) Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate
NO20055650D0 (no) Ruteinum (II)-komplekser for behandling av tumorer
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE328883T1 (de) Imidazopyridin-8-one
DE502004009491D1 (de) Thiaepothilone zur behandlung von krebserkrankungen
UY27768A1 (es) 2-(2,6- diclorofenil)-diarilimidazoles

Legal Events

Date Code Title Description
FG Grant or registration